Search Results

240 results for JNY

Johnson & Johnson (JNJ): The Dividend King of Kings

Reliable for more than 50 years, Johnson & Johnson is a dividend king. And given its recent Q1 earnings beat and increased guidance for the…

Are There Any Value Stocks Left? Yes…Yes There Are!

With major indexes hitting record highs, value investors are wondering if this means an end to value stock investing. The answer is no…

Are There Any Lurking Risks to the Stock Market Rally?

Most of these factors are likely to develop over the intermediate term and don’t represent much of a short-term problem.

Buy Ranking for Johnson & Johnson (JNJ) Kept

Johnson & Johnson Co (NYSE:JNJ) is ranked as a Buy using Louis Navellier’s Portfolio Grader stock evaluator, which incorporates his investing methodology. This represents no…

Don’t Press Any Bets This Week

Between the Fed decision and a quadruple witching expiration, this is not the time to initiate new positions.

7 Altcoins That Will Beat Bitcoin Any Day

While Bitcoin is getting all the attention thanks to its record-breaking run, prospective buyers should check out these crypto alternatives.

Buy These 3 Stocks on Any Earnings Dip

Google, SodaStream and Qualcomm don’t always beat earnings estimates, nor circumvent a post-earnings plunge. They do, however, always come back stronger.

Follow the Smart Money’s Lead on Any Correction

Large institutions have indicated that they are ready to pounce on weakness.

Is Any Metal Worth Trading Right Now?

From gold to palladium, traders have hammered away at just about anything metal in 2013. However, the charts finally show a couple bullish opportunities.

Five Reasons to Buy Stocks on Any Dips

We’re getting closer. It’s almost time for my debate with Louis Navellier.  If you haven’t heard, Louis and I have a friendly bet about the…

JNJ: A Little Leaner, But Is This Dividend Stalwart a Buy?

Johnson & Johnson’s Ortho-Clinical sale is a bit of a head-scratcher, but it doesn’t change the big picture much. JNJ stock still serves a purpose.

Expect Any Bounce to Be of the Dead Cat Variety

A move above 1,600 is likely before the market heads back down to better support.

Are There Any Winners from The ObamaCare Decision?

The Affordable Care Act was upheld on Constitutional grounds, and while there are implications to sort out and taxes to pay, it represents a play…

Don’t Put Any Stock in Denim

Companies might be able to sell jeans for $200 to $300 a pair, but it still doesn’t make them a worthwhile investment. Skip these big…

Wait for Confirmation Before Placing Any Bets

Charts show the market is at a critical juncture.

JNJ May Provide Some Relief in a Correction

Health care stock Johnson & Johnson (NYSE: JNJ) is one of the few bargains dividend stock worth buying now.

5 Must-See Charts for Any Trader

Things are certainly looking more bullish, but has the easy money already been made?

3 Midcap Stocks to Buy For Any Market

3 of the best midcap stocks to buy now, according to a top fund manager, include CBS Corp, Raymond James Financial and Joy Global

Natural Gas Stock Piedmont (PNY) is On Fire

Investors fled to high yielding, stable utilities like Piedmont Natural Gas Co. (NYSE: PNY) through the turbulent 2000-2002 bear market as well as in most…

How to Grow Your Wealth in Any Market

This year has felt especially chaotic due to the hotly contested election. But no one should confuse acknowledging the crazy environment we live in for…

Is There Any Hope for Lagging AMD Stock? Yes.

AMD stock is trailing its biggest rival by a considerable amount in 2024. That doesn’t mean it’s a writeoff.

Sleepy Johnson & Johnson (JNJ) Stock Could Finally Wake Up

If Johnson & Johnson (JNJ) deals for Actelion, it would be out of character. But it still could be a boon for JNJ stock.

The Biggest AI Story You Missed

Claude’s Mythos causes cybersecurity stocks to tank… the quantum threat to online security is coming fast… how Jonathan Rose is playing it… has the energy…

Johnson & Johnson a Safe Play for Income

JNJ’s financials are solid, and the company is making strides toward getting 11 new drugs approved by the end of 2015.

9 – 10 of 240 results